2. Search Result
Search Result
Results for "

CD36 and LIMPII analogous 1 (CLA-1)

" in MedChemExpress (MCE) Product Catalog:

2989

Inhibitors & Agonists

5

Screening Libraries

23

Fluorescent Dyes

210

Biochemical Assay Reagents

1759

Peptides

63

Inhibitory Antibodies

197

Natural
Products

349

Recombinant Proteins

17

Isotope-Labeled Compounds

278

Antibodies

23

Click Chemistry

117

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112847A
    Sulfosuccinimidyl oleate sodium
    35+ Cited Publications

    Sulfo-N-succinimidyl oleate sodium

    		 Mitophagy Inflammation/Immunology
    Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor of mitochondrial respiratory chain. Sulfosuccinimidyl oleate sodium binds the CD36 receptor on the surface of microglia. Anti-inflammatory effect [1] .
    Sulfosuccinimidyl oleate sodium
  • HY-113402
    Gamma-glutamylcysteine
    4 Publications Verification

    γ-Glu-Cys

    		 Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease [1] .
    Gamma-glutamylcysteine
  • HY-163541
    SMS121
    3 Publications Verification

    		 Scavenger Receptor Class B type I (SR-BI） Cancer
    SMS121 is a CD36 inhibitor with a KD values of about 5 µM. SMS121 reduces the uptake of lipids and inhibits cell viability in acute myeloid leukemia cells. SMS121 has antitumor activity [1].
    SMS121
  • HY-134957
    VT107
    5+ Cited Publications

    		 YAP Cancer
    VT-107, as an analogous to VT104, is an orally active and potent pan-TEAD auto-palmitoylation inhibitor. VT-107 can be used for the research of cancer [1].
    VT107
  • HY-P5322
    Thrombospondin (TSP-1)-derived CD36 binding motif

    		Transmembrane Glycoprotein Cardiovascular Disease Cancer
    Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer [1] .
    Thrombospondin (TSP-1)-derived CD36 binding motif
  • HY-113402A
    Gamma-glutamylcysteine TFA
    4 Publications Verification

    γ-Glu-Cys TFA

    		 Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease [1] .
    Gamma-glutamylcysteine TFA
  • HY-15941
    5(6)-FITC
    2 Publications Verification

    Fluorescein 5(6)-isothiocyanate; Fluorescein isothiocyanate 5- and 6- isomers

    		 Fluorescent Dye Others
    5(6)-FITC (Fluorescein 5(6)-isothiocyanate) is an amine-reactive derivative of a fluorescent dye, characterized by high absorbance and excellent fluorescence quantum yield. The isothiocyanate group of FITC can react with various functional groups on proteins, including amines, thiols, imidazoles, tyrosines and carbonyls, enabling the labeling of proteins such as antibodies and lectins. 5(6)-FITC has a wide range of applications, including flow cytometry, immunofluorescence, protease assays and conjugation. The maximum excitation/emission wavelengths are 492/518 nm [1] .
    5(6)-FITC
  • HY-NP165
    Advanced glycation end products

    AGEs

    		 Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Advanced glycation end products (AGEs) are a series of stable compounds generated through non-enzymatic reactions between reducing sugars and proteins, lipids, or nucleic acids. Advanced glycation end products are often used as targets to evaluate the inhibitory effects of anti-glycation compounds. Advanced glycation end products can be applied to research on diabetes, cardiovascular and cerebrovascular diseases, inflammation, aging, and other conditions [1] .
    Advanced glycation end products
  • HY-15940
    5(6)-Carboxyfluorescein
    5 Publications Verification

    5(6)-FAM; 5-(and-6)-Carboxyfluorescein mixed isomers

    		 Fluorescent Dye Cancer
    5(6)-Carboxyfluorescein (5(6)-FAM) is an amine-reactive pH-sensitive green fluorescent probe. 5(6)-Carboxyfluorescein (5(6)-FAM) can be used to label proteins, peptides and nucleotides. 5(6)-Carboxyfluorescein can be used for the detection of tumour areas in vivo [1] .
    5(6)-Carboxyfluorescein
  • HY-30216
    (R)-Leucic acid

    D-α-Hydroxyisocaproic acid

    		 Amino Acid Derivatives Endogenous Metabolite Metabolic Disease
    (R)-Leucic acid (D-α-Hydroxyisocaproic acid) is an orally active D-isomer of the α-hydroxy analogue of Leucine (HY-N0486). (R)-Leucic acid is a metabolite of Lactobacillus and can promote intestinal fatty acid absorption by upregulating CD36 expression. (R)-Leucic acid can be used to study microbe-host interactions and the regulation of lipid metabolism by probiotics [1] .
    (R)-Leucic acid
  • HY-116003
    12,13-DiHOME

    		Endogenous Metabolite Metabolic Disease
    12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders [1].
    12,13-DiHOME
  • HY-W561907
    IMipenem and cilastatin sodium

    		Antibiotic Bacterial Infection
    IMipenem and cilastatin sodium is a broad-spectrum Carbapenem Antibiotic combination. Imipenem (HY-B1369A) is a Carbapenem antibiotic. IMipenem demonstrates excellent activity against gram-positive and gram-negative aerobic and anaerobic organisms. Cilastatin (HY-A0166) is a renal Dehydropeptidase inhibitor that inhibits the metabolism of Imipenem by renal brush-border enzymes, thus increasing imipenem concentrations in urine [1].
    IMipenem and cilastatin sodium
  • HY-177451
    Glyceryl mono and dicaprylocaprate

    		Biochemical Assay Reagents Others
    Glyceryl mono and dicaprylocaprate is a mixture of glyceryl monoesters and diesters.
    Glyceryl mono and dicaprylocaprate
  • HY-128671
    6-​Thioinosine

    6TI; 6-Mercaptopurine riboside

    		 PPAR LXR JNK NO Synthase Metabolic Disease
    6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction [1].
    6-​Thioinosine
  • HY-NP203
    High density lipoprotein (human)

    HDL (human)

    		 Apolipoprotein NO Synthase LPL Receptor Akt PI3K p38 MAPK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    High density lipoprotein (human) (HDL (human)) is a human-derived high-density lipoprotein. High density lipoprotein can cross the blood-brain barrier, and partially acts on endothelial nitric oxide synthase (eNOS) by activating surface receptors such as SR-B1 and S1P3R, as well as intracellular signaling cascades involving Akt, PI3K and MAPK, thereby inducing the production of NO in endothelial cells. High density lipoprotein (human) can be used in research related to type 2 diabetes, Alzheimer's disease, cancer and atherosclerosis [1] .
    High density lipoprotein (human)
  • HY-P99274
    Xentuzumab
    1 Publications Verification

    BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

    		 IGF-1R Cancer
    Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation [1].
    Xentuzumab
  • HY-DY3003
    Tissue and Cell Fixative (4% Paraformaldehyde, PFA)

    		Biochemical Assay Reagents Others
    Tissue and Cell Fixative (4% Paraformaldehyde, PFA) is mainly composed of paraformaldehyde, phosphate, and deionized water, with a pH of 7.0-7.4. Tissue and Cell Fixative (4% Paraformaldehyde, PFA) is suitable for fixing most tissues and cells, and can effectively protect the morphology and structure of tissues and cells as well as nucleic acids.
    Tissue and Cell Fixative (4% Paraformaldehyde, PFA)
  • HY-P3970A
    KRFK TFA
    4 Publications Verification

    		 TGF-β Receptor Inflammation/Immunology
    KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach [1].
    KRFK TFA
  • HY-P990352
    Anti-CD36 Antibody

    Ona36

    		 Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD36 Antibody
  • HY-126726
    KOdiA-PC

    		Biochemical Assay Reagents Others
    Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.
    KOdiA-PC
  • HY-P3970
    KRFK

    		TGF-β Receptor Inflammation/Immunology
    KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach [1].
    KRFK
  • HY-155938
    Cyano-myracrylamide
    1 Publications Verification

    		 Acyltransferase Neurological Disease Inflammation/Immunology Cancer
    Cyano-myracrylamide is an inhibitor of zinc finger DHHC domain-containing palmitoyltransferase 20 (zDHHC20) with an IC50 value of 1.35 µM. Cyano-myracrylamide also inhibits the S-Acylation of EGFR and CD36. Cyano-myracrylamide also inhibits S-acylation of Legionella E3 ligase GobX, MyD88, and Ras, which are substrates of zDHHC20, zDHHC9, and zDHHC6, respectively, in HEK293T cells expressing recombinant Legionella GobX, recombinant human MyD88, or endogenous Ras [1].
    Cyano-myracrylamide
  • HY-W040255
    1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine

    PGPC

    		 Ferroptosis FABP Caspase Interleukin Related Apoptosis Inflammation/Immunology
    1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is an oxidized phospholipid. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine reduces the viability of HUVECs, increases the levels of ferrous ions and lipid peroxidation, promotes the production of superoxide anions, and decreases the levels of glutathione and GPX4 in cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine upregulates the mRNA and protein levels of FABP3 in HUVECs, impairs mitochondrial membrane potential, and induces ferroptosis-related changes as well as mitochondrial dysfunction and damage. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine activates caspase-11 and promotes the continuous release of IL-1β from macrophages and dendritic cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibits the proliferation of aortic smooth muscle cells and induces apoptosis in these cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is applicable to relevant research on atherosclerosis [1] .
    1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine
  • HY-W007056
    Fmoc-N-me-Trp(Boc)-OH

    		Amino Acid Derivatives Biochemical Assay Reagents Drug Intermediate Infection
    Fmoc-N-me-Trp(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize peptide antibiotics with antibacterial activity against Pseudomonas aeruginosa [1].
    Fmoc-N-me-Trp(Boc)-OH
  • HY-163649
    A17

    		AMPK Metabolic Disease
    A17 is a bile acid analog with anti-non-alcoholic steatohepatitis (NASH) and anti-inflammatory activities. A17 reduces fatty acid (FA) uptake and promotes FA oxidation though inhibiting fatty acid translocase (Cd36) expression and activating AMPKα. A17 can be used for NASH research [1].
    A17
  • HY-P10183
    CD36 Peptide P (139-155), Cys conjugated

    Cys-CD36(139-155)

    		 Transmembrane Glycoprotein Inflammation/Immunology
    CD36 Peptide P (139-155), Cys conjugated is a Cys labelled CD36 Peptide, and can inhibit the immunoadsorption of CD36 by OKM5 [1].
    CD36 Peptide P (139-155), Cys conjugated
  • HY-RS16502
    Cd36 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cd36 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd36 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd36 Mouse Pre-designed siRNA Set A
    Cd36 Mouse Pre-designed siRNA Set A
  • HY-112847B
    (E/Z)-Sulfosuccinimidyl oleate sodium

    (E/Z)-Sulfo-N-succinimidyl oleate sodium

    		 Transmembrane Glycoprotein Mitochondrial Metabolism Drug Isomer Inflammation/Immunology
    (E/Z)-Sulfosuccinimidyl oleate sodium is the racemate of (E)-Sulfosuccinimidyl oleate sodium and (Z)-Sulfosuccinimidyl oleate sodium. Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long-chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor of the mitochondrial respiratory chain. Sulfosuccinimidyl oleate sodium binds to the CD36 receptor on the surface of microglial cells. Sulfosuccinimidyl oleate sodium exhibits anti-inflammatory effects [1] .
    (E/Z)-Sulfosuccinimidyl oleate sodium
  • HY-112847
    Sulfosuccinimidyl oleate

    Sulfo-N-succinimidyl oleate

    		 Mitophagy Inflammation/Immunology
    Sulfosuccinimidyl oleate (Sulfo-N-succinimidyl oleate) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate is a potent and irreversible inhibitor of mitochondrial respiratory chain. Sulfosuccinimidyl oleate binds the CD36 receptor on the surface of microglia. Anti-inflammatory effect [1] .
    Sulfosuccinimidyl oleate
  • HY-70027A
    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride

    		MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.
    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride
  • HY-168049
    ZLY06

    		PPAR Akt Metabolic Disease
    ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis [1] .
    ZLY06
  • HY-P10184
    CD36 Peptide P (93-110), Cys conjugated

    		Transmembrane Glycoprotein Inflammation/Immunology
    CD36 Peptide P (93-110), Cys conjugated is a Cys labelled CD36 Peptide, and can block binding of CD36 to immobilized thrombospondin and partially inhibited collagen-induced platelet aggregation [1].
    CD36 Peptide P (93-110), Cys conjugated
  • HY-135297
    Mono-and diglycerides

    		Biochemical Assay Reagents Others
    Mono-and diglycerides is formed by triglycerides being broken down by pancreatic lipase in the gastrointestinal lumen. Mono-and diglycerides is a food additive used as a nonionic emulsifier and mainly present in food fats [1] .
    Mono-and diglycerides
  • HY-P2498A
    Cathepsin D and E FRET Substrate acetate

    		Cathepsin Cancer
    Cathepsin D and E FRET Substrate acetate is a fluorogenic substrate for cathepsins D and E and not for B, H or L. The cleavage occurs at the Phe-Phe amide bond resul. Cathepsin D and E FRET Substrate is a valuable tool for routine assays and for mechanistic studies on cathepsins E and D [1].
    Cathepsin D and E FRET Substrate acetate
  • HY-146005
    Tau-aggregation and neuroinflammation-IN-1

    		Microtubule/Tubulin Neurological Disease Inflammation/Immunology
    Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats [1].
    Tau-aggregation and neuroinflammation-IN-1
  • HY-139637
    (±)-Silybin

    Silibinin (mixture of Silybin A and Silybin B)

    		 Apoptosis Cancer
    (±)-Silybin is the racemate of Silybin (HY-N0779A). Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity [1] .
    (±)-Silybin
  • HY-D2776
    Primary antibody and secondary antibody eluent, specially for mIHC experiments

    		Biochemical Assay Reagents Others
    Primary antibody and secondary antibody eluent, specially for mIHC experiments is an eluent used for mIHC (multiple immunohistochemistry).
    Primary antibody and secondary antibody eluent, specially for mIHC experiments
  • HY-W067425
    2-(4-Hydroxyphenyl)propionic acid

    		Endogenous Metabolite Metabolic Disease
    2-(4-Hydroxyphenyl)propionic acid (Compound 1) is an aromatic carboxylic acid, which can be converted into its R and S glucosyl esters and glucosides by root culture of P. ginseng (Pg-1) [1].
    2-(4-Hydroxyphenyl)propionic acid
  • HY-W129233
    Dihydroartemisinin (mixture of α and β isomers)

    Dihydroartemisinin (α,β mixture)

    		 Parasite Autophagy Apoptosis Infection Cancer
    Dihydroartemisinin (mixture of α and β isomers) is an anti-malaria and anticancer agent, as well as an active metabolite of artemisinin and its derivatives. Dihydroartemisinin exerts anticancer effects through various molecular mechanisms, such as inhibiting proliferation, inducing apoptosis, inhibiting tumor metastasis and angiogenesis, promoting immune function, inducing autophagy and endoplasmic reticulum stress [1].
    Dihydroartemisinin (mixture of α and β isomers)
  • HY-W008024
    Fmoc-Dab(Boc)-OH

    		Amino Acid Derivatives Others
    Fmoc-Dab(Boc)-OH is an amino acid derivative with an Fmoc protecting group that can be used to synthesize somatostatin analogs that inhibit neointima formation induced by balloon injury in rats without altering growth hormone release. Fmoc-Dab(Boc)-OH can be used for the synthesis of peptides [1] .
    Fmoc-Dab(Boc)-OH
  • HY-RS02237
    CD36 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CD36 Human Pre-designed siRNA Set A contains three designed siRNAs for CD36 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD36 Human Pre-designed siRNA Set A
    CD36 Human Pre-designed siRNA Set A
  • HY-RS22934
    Cd36 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cd36 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd36 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd36 Rat Pre-designed siRNA Set A
    Cd36 Rat Pre-designed siRNA Set A
  • HY-113402R
    Gamma-glutamylcysteine (Standard)

    γ-Glu-Cys (Standard)

    		 Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis Inflammation/Immunology
    Gamma-glutamylcysteine (Standard) is the analytical standard of Gamma-glutamylcysteine. This product is intended for research and analytical applications. Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
    Gamma-glutamylcysteine (Standard)
  • HY-119404
    Diproqualone

    (±)-Diproqualone

    		 GABA Receptor Neurological Disease Inflammation/Immunology
    diproqualone is methaqualone analogous with sedative, anxiolytic, anti-inflammatory and analgesic properties [1].
    Diproqualone
  • HY-125554
    KDdiA-PC

    		Transmembrane Glycoprotein Cardiovascular Disease
    KDdiA-PC is one of the most potent CD36 ligands in oxidized LDL (oxLDL) [1].
    KDdiA-PC
  • HY-W419140
    AND-017

    		Drug Intermediate Others
    AND-017 is an important intermediate for Rocuronium Bromide (HY-17440) [1].
    AND-017
  • HY-150184
    And1-IN-1

    		DNA/RNA Synthesis Cancer
    And1-IN-1 is a potent And1 inhibitor with an IC50 of 2.08 μM. And1-IN-1 binds to the N-terminus of And-1 and induces a conformational change in And-1, which promotes the interaction of And-1 with E3 ligase CUL4B for ubiquitin-mediated degradation. And1-IN-1 suppresses the growth of a broad range of cancers and resensitizes platinum-resistant ovarian cancer cells to platinum agents. And1-IN-1 can be used for the studies of ovarian cancer and breast cancer [1].
    And1-IN-1
  • HY-70027
    p53 and MDM2 proteins-interaction-inhibitor (chiral)

    		MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.
    p53 and MDM2 proteins-interaction-inhibitor (chiral)
  • HY-P2696
    EP 80317

    		Transmembrane Glycoprotein Cardiovascular Disease
    EP 80317 is a selective CD36 ligand. EP 80317 protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 can be used for the study of cardiovascular disease [1].
    EP 80317
  • HY-108385
    Ochratoxin A-D4

    		Isotope-Labeled Compounds Endogenous Metabolite DNA/RNA Synthesis PPAR Reactive Oxygen Species (ROS) Apoptosis Fungal Inflammation/Immunology Cancer
    Ochratoxin A-D4 (Phe-​OTA-D4) is the deuterium labeled Ochratoxin A. Ochratoxin A is an orally active food-borne mycotoxin that can cross the blood-brain barrier. Ochratoxin A is a secondary metabolite of fungi belonging to the genera Aspergillus and Penicillium, and is classified as a Group 2B carcinogen. Ochratoxin A exerts its effects through multiple pathways, including inducing oxidative stress, inhibiting mitochondrial respiration, causing oxidative DNA damage, disrupting the PPAR-γ-CD36 axis, inducing immunosuppression, generating ROS, mediating mitochondria-dependent apoptosis, inhibiting glutamate uptake, triggering demyelination and neuroinflammation, inducing DNA hypomethylation, and inhibiting cell proliferation. Ochratoxin A can induce nephrotoxicity, hepatotoxicity, immunotoxicity, and neurotoxicity, and also exhibits mutagenicity, teratogenicity, and carcinogenicity.
    Ochratoxin A-D4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: